ArticleJournal of neuro-oncology2025
Engineering overexpressing SYNGR1 inhibited the progression of GBM cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction of an actin cytoskeleton-related gene signature for predicting prognosis and therapeutic response in glioblastoma: based on machine learning.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundGlioblastoma (GBM) is the most common and aggressive glioma subtype in adults, characterized by disrupted lipid homeostasis. The accumulation of lipid droplets (LDs) is involved in the actin cytoskeleton remodeling in different types of cells, the intracellular fibroblast growth factor 1 (FGF1) plays an important role in this process. The stability of cytoskeleton is crucial for the proliferation, invasion and other malignant behavior of GBM. The synaptic gyrus protein 1 (synaptogyrin 1, SYNGR1) is closely correlated with the progression of various tumours, but there have been no reports of research in the field of glioma. This research was conducted to investigate whether the overexpression of SYNGR1 was involved in regulating the malignant biological behaviour of GBM cells and its potential regulatory mechanism, especially whether the LDs accumulation is involved in the remodeling of the actin cytoskeleton in GBM cells.
methodsThe UCSC Xena database and GEPIA database were used to analyze the correlation between the expression level of SYNGR1 and the survival time of glioma patients. Engineering Lentiviruses were used to establish cells with stable overexpression of SYNGR1, FGF1, or both. The proliferation, invasion, and cytoskeleton of glioma cells (U251, LN229, U118) were detected by cell counting kit-8 (CCK8), 5-ethynyl-2'-deoxyuridine (EdU), immunofluorescence(IF), colony formation, adhesion, and transwell assays. Intracellular LDs were detected by the lipid droplet red fluorescence assay with Nile red. The cell cycle distribution and apoptosis rate of the cells were assessed using flow cytometry analysis. Bioinformatics analysis, IF, RNA sequencing, and western blot analysis were used to measure the expression levels of target proteins. The protein from HA and HT22 cell lines served as control was detected by western blot analysis. The Gl261 cell line and C57BL/6 mouse were used to construct C57BL/6 mouse glioblastoma model. Animal MRI was used to examine tumor size.
resultsSYNGR1 expression was significantly reduced in GBM. Overexpression of SYNGR1 significantly inhibited the LDs accumulation, proliferation, invasion, adhesion, and other malignant processes in GBM cells in vitro. Moreover, SYNGRI overexpression inhibited the growth of intracranial gliomas in vivo and prolonged survival of C57BL/6 model mice. Mechanistic exploration revealed that the overexpression of SYNGR1 had an antiglioma effect by inhibiting the LDs accumulation and remodeling the cytoskeleton via the downregulation of the intracellular FGF1, while FGF1 overexpression could reverse the antiglioma effect of SYNGR1.
conclusionsThe intracellular FGF1 played an important role in maintaining the homeostasis of LDs and the actin cytoskeleton, which promoted the malignant progression of GBM cells. Engineering overexpressing SYNGR1 could effectively inhibit the malignant biological behaviors, such as the proliferation, adhesion, and invasion, as well as promote the apoptosis of glioma cells by suppressing the intracellular FGF1-mediated LDs accumulation and cytoskeleton remodeling.
Indexed as
Identifiers
40478501What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.